IGF1R inhibitors such as IMC-A12 and picropodophyllin effectively suppress GBM growth in preclinical models, reducing tumor proliferation and angiogenesis.288,289 These findings highlight IGF1R as a promising therapeutic target, warranting further investigation into its role in chemoresistance and the potential benefits of combination therapies integrating IGF1R inhibitors with standard GBM treatments. This evidence concerns the gene IGF1R and glioblastoma.